0 32

Cited 2 times in

Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma

Authors
 Hye Ryun Kim  ;  Chang Geol Lee  ;  Eun Chang Choi  ;  Joo Hang Kim  ;  Yoon Woo Koh  ;  Byoung Chul Cho 
Citation
 Head & Neck, Vol.38(Suppl. 1) : 1653-1659, 2016 
Journal Title
 Head & Neck 
ISSN
 1043-3074 
Issue Date
2016
MeSH
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; Carcinoma, Squamous Cell ; Chemoradiotherapy* ; Cisplatin/administration & dosage* ; Drug Combinations ; Female ; Fluorouracil ; Head and Neck Neoplasms/therapy* ; Humans ; Induction Chemotherapy* ; Male ; Middle Aged ; Oxonic Acid/administration & dosage* ; Taxoids/administration & dosage* ; Tegafur/administration & dosage* ; Young Adult
Keywords
S-1 ; docetaxel ; head and neck ; induction chemotherapy ; squamous cell carcinoma
Abstract
BACKGROUND: The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. METHOD: Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. RESULTS: The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. CONCLUSION: Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152473
DOI
10.1002/hed.24294
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
Yonsei Authors
고윤우(Kho, Yoon Woo) ; 김주항(Kim, Joo Hang) ; 김혜련(Kim, Hye Ryun) ; 이창걸(Lee, Chang Geol) ; 조병철(Cho, Byoung Chul) ; 최은창(Choi, Eun Chang)
사서에게 알리기
  feedback
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/hed.24294/abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse